Canada Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institut
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCanada Cell Therapy Manufacturing Market By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Source (In-House v/s Contract Manufacturing), By Application (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institut
Canada cell therapy manufacturing market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the high prevalence of cancer and other target diseases and increasing R&D investments in pharmaceutical companies across the region. Similarly, increasing number of clinical trials and approval of stem cell-based therapies from regulatory bodies will further drive the growth of the Canada cell therapy manufacturing market during the forecast period. Also, growing financial assistance from governments, private vendors, and NGOs are anticipated to propel the growth of the Canada cell therapy manufacturing market during the forecast period. Manufacturers are involved in developing and launching various types of technologies for cell therapy manufacturing, which will further propel the growth of the Canada cell therapy manufacturing market during the forecast period.
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a major driver for the growth of the Canada cell therapy manufacturing market. Chronic diseases such as cancer, diabetes, cardiovascular diseases, and neurological disorders are among the leading causes of death and disability across the world. Traditional treatments for these diseases, such as chemotherapy, radiation therapy, and surgery, have limitations and may not always be effective. As a result, there is a growing interest in cell-based therapies that offer the potential for more targeted and effective treatments. Cell therapies are a promising new approach to treating chronic diseases. They involve using living cells to replace or repair damaged or diseased cells in the body. Cell therapies have shown promising results in treating a variety of conditions, including cancer, heart disease, and neurological disorders. As such, the increasing prevalence of chronic diseases has created a growing demand for cell-based therapies. In Canada, the increasing prevalence of chronic diseases has led to a greater focus on developing innovative cell-based therapies. Canadian researchers and companies are actively working to develop new cell therapies and are making significant progress in this area. The Canadian government is also investing in research and development to support the growth of the cell therapy industry.
Supportive Government Policies
Supportive government policies are a key driver for the growth of the Canada cell therapy manufacturing market. The government provides funding for research and development in the field of cell therapy. This funding supports basic and applied research that is focused on developing new cell-based therapies and advancing existing ones. The government offers tax incentives for companies that invest in research and development, as well as those that invest in the production and commercialization of cell-based therapies. These incentives help to reduce the costs of developing and manufacturing these therapies. The government offers grants and funding to startups and small businesses that are focused on developing cell-based therapies. This support helps to reduce the barriers to entry for smaller companies and encourages innovation in the industry. The government is investing in infrastructure and workforce development to support the growth of the cell therapy industry. This includes funding for research facilities, manufacturing facilities, and training programs for workers in the industry.
Technological Advancements
Technological advancements are a major driver for the growth of the Canada cell therapy manufacturing market. Advances in cell biology, genetics, and engineering have paved the way for the development of new and innovative cell-based therapies that will drive the growth of the market during the forecast period. Technological advancements have led to a better understanding of how cells work and how they can be used to treat diseases. This has paved the way for the development of new and innovative cell-based therapies that are more effective and have fewer side effects than traditional treatments. Gene editing and gene therapy are emerging as promising new approaches to treat diseases. These technologies enable researchers to modify the genetic material of cells to correct genetic defects or enhance their therapeutic potential. Technological advancements have led to the development of new manufacturing processes for cell-based therapies. These processes are more efficient, scalable, and cost-effective than traditional manufacturing methods, making it easier to produce cell-based therapies at a commercial scale. Automation and robotics are being integrated into the cell therapy manufacturing process, improving the efficiency and reliability of the manufacturing process. This has led to reduced costs, faster production times, and improved quality control.
Research and Development
Research and development (R&D) are key drivers of the growth of the Canada cell therapy manufacturing market. The development of new and innovative cell-based therapies requires significant investment in R&D to discover and develop new therapies, optimize manufacturing processes, and demonstrate safety and efficacy through clinical trials. R&D is driving the development of new cell therapies that can be used to treat a wide range of diseases, including cancer, heart disease, and neurological disorders. This includes the identification and characterization of new cell types, as well as the development of new technologies for manipulating and engineering cells. R&D is also focused on optimizing manufacturing processes to improve the efficiency, scalability, and cost-effectiveness of cell therapy production. This includes the development of new technologies for culturing and expanding cells, as well as the integration of automation and robotics to streamline the manufacturing process. R&D is also critical for demonstrating the safety and efficacy of cell-based therapies through clinical trials. These trials are necessary to obtain regulatory approval and to bring new therapies to market. R&D is often conducted through collaboration and partnerships between academia, industry, and government. These collaborations bring together expertise from different fields and help to accelerate the development of new therapies and technologies.
Growing Demand for Personalized Medicines
The growing demand for personalized medicines is a key driver for the growth of the Canada cell therapy manufacturing market. Personalized medicine refers to the use of a patient's genetic information, lifestyle, and other factors to tailor treatments to their individual needs. Cell-based therapies are particularly well-suited for personalized medicine because they can be customized to a patient's specific condition and genetic profile. Cell-based therapies can be tailored to a patient's specific condition and genetic profile, making them ideal for personalized medicines. Advances in cell biology, gene editing, and other technologies are making it possible to develop patient-specific therapies that are more effective and have fewer side effects than traditional treatments. Precision medicine is an approach to healthcare that emphasizes the customization of treatments to individual patients. Cell-based therapies are an important component of precision medicine, and the growing demand for personalized medicine is driving increased investment in this area. The growing demand for personalized medicine is driving the expansion of cell therapy applications beyond traditional areas such as cancer and blood disorders. Cell-based therapies are being developed for a wide range of conditions, including autoimmune diseases, neurological disorders, and cardiovascular disease. The demand for personalized medicine is also driving changes in regulatory and reimbursement policies. Regulators and payers are increasingly recognizing the value of personalized medicine and are working to create a regulatory and reimbursement framework that supports the development and commercialization of these therapies.
Recent Development
- In January 2022, STEMCELL Technologies announced the opening of a new 66,000 square-foot manufacturing facility in Burnaby, British Columbia. The facility will produce cell therapy products for clinical trials and commercial use and will support the development of stem cell-based therapies for a range of conditions.
- In November 2021, the Center for Commercialization of Regenerative Medicine (CCRM) and CCRM Australia announced a partnership to provide manufacturing services for CAR-T cell therapies. The partnership will leverage the manufacturing expertise of both organizations to support the development and commercialization of cell-based therapies in Canada and Australia.
- In September 2021, Avicanna Inc. and University Health Network announced a collaboration to develop and manufacture neural stem cell-based therapies for neurological disorders. The partnership will leverage Avicanna's expertise in cannabis-based therapies and the University Health Network's expertise in cell-based therapies to advance the development of new treatments.
- In August 2021, the Government of Canada announced $25 million in funding for the Center for Commercialization of Regenerative Medicine (CCRM) to support the development and commercialization of cell-based therapies. The funding will support the establishment of a new manufacturing facility in Toronto, as well as the development of new cell therapies for a range of conditions.
Download Free Sample Report
Market Segmentation
The Canada cell therapy manufacturing market can be segmented by therapy, source of cell, source, application, end user, and region. Based on therapy, the Canada cell therapy manufacturing market can be segmented into T-Cell therapies, dendritic cell therapies, tumor cell therapies, and stem cell therapies. Based on source of cell, the Canada cell therapy manufacturing market can be divided into autologous v/s allogenic. Based on source, the Canada cell therapy manufacturing market can be divided into in-house v/s contract manufacturing. Based on application, the Canada cell therapy manufacturing market can be segmented into oncology, cardiovascular diseases, orthopedic diseases, and others. Based on end user, the Canada cell therapy manufacturing market can be grouped into pharmaceutical & biotechnology companies, academic & research institutes, and others.
Market Players
Novartis Pharmaceuticals Canada Inc, Hoffmann-La Roche Ltd., Gilead Sciences Inc, Thermo Fisher Scientific Inc, Catalent Ontario Ltd., Takeda Canada Inc., and Amgen Canada Inc. are some of the leading players operating in the Canada cell therapy manufacturing market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | By Therapy By Source of Cell By Source By Application By End User By Region |
| Regional scope | Ontario region; Quebec region; Alberta region; British Columbia region; Saskatchewan and Manitoba region; Rest of Canada |
| Key companies profiled | Novartis Pharmaceuticals Canada Inc, Hoffmann-La Roche Ltd., Gilead Sciences Inc, Thermo Fisher Scientific Inc, Catalent Ontario Ltd., Takeda Canada Inc., Amgen Canada Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy